Vizgen closed a $48 million financing round led by Arch Venture Partners, M Ventures and Northpond Ventures to scale commercial operations for its spatial transcriptomics platform, expand consumables and software offerings, and march toward profitability. CEO Rob Carson highlighted product expansions, turnaround improvements, and global field support plans tied to the funding. In a complementary commercial move, Singleron Biotechnologies signed an exclusive distribution agreement with DKSH for Australia and New Zealand to sell single-cell multiomics products, extending spatial and single-cell tool access in APAC. DKSH will supply local sales, service and technical support for Singleron’s workflow. Taken together, the transactions reflect growing commercial momentum in spatial and single-cell multiomics as companies scale instrument, consumable and service models globally. Investors and providers are prioritizing field presence, consumables roadmaps, and software analytics to convert academic adoption into reproducible revenue streams.